Abstract

This meeting focuses on immune escape mechanisms, immune tolerance, the role of immune effector and suppressor cells as well as the tumor microenvironment in this context, and the modulation of these different processes. In addition, the modes and efficacy of different cancer immunotherapeutic strategies and targeted therapies alone and in combination as well as their influence on the immune escape and immune suppressive activity will be an important topic. This meeting is expected to attract a broad range of scientists (e.g., biologists, biochemists, immunologists, cancer researchers) and clinicians (oncologists, pathologists, radiologists) and will bridge basic, translational and clinical research. The speakers invited represent basic researchers, clinicians and employees of the pharmaceutical industry. There will be a strong clinical focus to the program, in particular regarding different therapeutic strategies including cancer immunotherapy and targeted therapies, which have recently been successfully implemented for the therapy of many cancers including chronic myeloid leukemia, breast carcinoma, non-small lung carcinoma, colorectal cancer, kidney cancer and melanoma. This meeting is being held in conjunction with "Purinergic Signaling."